Last checked at 9 Apr 2021 11:01
9 April 2021
Intuitive Investments Group plc
Issue of Shares and Total Voting Rights
Intuitive Investments Group plc (AIM: IIG) ("IIG" or the "Company"), a closed-end investment company focussed on the life sciences sector, announces that it has issued 22,624 new ordinary shares of 1p each in the Company ("Ordinary Shares") to Julian Baines, a member of the Company's investment Advisory Panel. The new Ordinary Shares have been issued at Julian's request in lieu of his annual Advisory Panel fee for the year to 14 December 2021 of £5,000. The new Ordinary Shares have been issued at yesterday's closing mid-price of 22.1p.
Application has been made to the London Stock Exchange for the new Ordinary Shares to be admitted to trading on AIM and it is expected trading will commence at 8.00 a.m. on 15 April 2021 ("Admission").
Following Admission, the total number of Ordinary Shares in the Company in issue will be 40,441,824 with one vote per share. This figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules. There are no shares held in treasury.
For further information, please contact:
Intuitive Investments Group plc | www.iigplc.com |
David Evans, Executive Chairman Robert Naylor, CEO | Via Walbrook PR |
|
|
Strand Hanson Limited - Nominated Adviser | +44 (0) 20 7409 3494 |
James Harris / James Dance / James Bellman
|
|
Turner Pope Investments (TPI) Ltd - Broker | +44 (0) 20 3657 0050 |
Andrew Thacker / Zoe Alexander |
|
|
|
Walbrook PR Limited - Media & Investor Relations | +44 (0)20 7933 8780 or intuitive@walbrookpr.com |
Sam Allen / Paul McManus | +44 (0)7502 558 258 / +44 (0) 7980 541 893 |
About Intuitive Investments Group plc
The Company is a newly established investing company, seeking to provide investors with exposure to a portfolio concentrating on fast growing and/or high potential Life Sciences businesses operating predominantly in the UK, continental Europe and the US, utilising the Board's experience and in particular that of the Chairman, David Evans, to seek to generate capital growth over the long term for shareholders.